IVPharma & Life Sciences
AI built for the regulated
edges of biopharma.
Pharmaceutical and life sciences organizations operate under GxP, FDA, and privacy regimes that make generic AI tools structurally unusable. Cara partners with pharma manufacturers, CROs, and commercial operations teams on workflows where AI can compress meaningful time — patient support enrollment, HCP engagement, trial intake, RWE generation — without taking shortcuts on regulatory posture.
Sub-practices
Where our work tends to sit.
Patient Support Programs
Copay, hub, and PAP programs. AI inside patient enrollment, benefits verification, adherence, and outcomes tracking.
HCP Engagement
Field-force enablement, HCP portals, and MSL-driven engagement. AI that respects promotional rules and HCP workflows.
Clinical Trials
Trial protocol authoring, site activation, patient recruitment, and eCRF operations. AI inside the operational machinery of trials.
Real-World Evidence
RWE generation from EHR, claims, and registry data. AI that accelerates cohort construction, endpoint extraction, and study design.
Commercial Operations
Field targeting, incentive compensation, brand analytics. AI inside the commercial operations of a brand launch.
Medical Affairs
MSL teams, medical information, and publication planning. AI for medical-information response, literature surveillance, and scientific communications.
Patterns
Where Cara sits in the work.
A representative flow — not a template. Every engagement shapes its own pattern around the partner’s actual constraints.
Example engagements
Patterns we keep seeing.
Patient support enrollment automation
AI that runs benefits verification, processes enrollment forms, and coordinates insurance and copay logic — compliant with PSP regulatory requirements.
HCP portal & engagement
HCP-facing portals with AI-assisted medical information, sample requests, and educational content — within promotional and MLR guardrails.
Clinical trial intake & screening
AI that reviews potential-patient records against trial inclusion/exclusion criteria and surfaces eligible candidates to investigators.
RWE cohort construction
AI-assisted cohort identification from EHR and claims data — with the audit trails RWE studies require.
Adverse event surveillance & MedInfo
Agents that triage MedInfo inquiries, draft responses, and flag potential AEs for PV review — GxP-aware.
Common questions
What partners ask before
they get on the call.
- Is Cara compliant with PSP, GxP, and MLR review?
- Yes. Patient support program work runs under HIPAA and PSP-specific policy, with copay-stacking, AKS, and beneficiary inducement guardrails enforced in software. HCP-facing systems route through MLR with version control and approval audit. Trial-related work is built to GxP — validated environments, traceable changes, and 21 CFR Part 11 controls where applicable.
- Which workflows does Cara prioritize in pharma?
- Patient support enrollment automation (BV, PA packet, copay logic, adherence), HCP portal and engagement (within promotional and MLR rails), clinical trial intake and screening, RWE cohort construction, and adverse-event surveillance / MedInfo response.
- Does Cara work with manufacturers directly or through CROs and hubs?
- Both. We engage with brand and patient-services leadership at manufacturers, with hub and SP operators, and with CROs on trial-operations workflows. Many engagements span both sides — for example, a manufacturer brand team and the hub vendor running the program.
- How does Cara handle multi-stakeholder data — patient, prescriber, payer, hub?
- Cara designs the data model and entitlement logic so each stakeholder sees only what they should — patients see their case, prescribers see their patients, hub agents see their queue, brand teams see aggregate analytics. Audit trails capture who saw what, when.
- Can Cara help with adverse-event detection and pharmacovigilance?
- Yes. AI agents triage MedInfo inquiries, flag potential AEs against case-report rules, and prepare structured records for PV review. The system is designed to support PV signal detection, not replace it — every flagged case routes to a human reviewer.
“The hardest AI engineering in life sciences is not the model. It is the regulatory posture the model has to operate inside.”